Abstract
Inflammation, endothelial dysfunction, and platelet activation contribute to the prothrombotic pro-inflammatory state associated with AF. Inflammatory biomarkers, such as C-reactive protein and interleukin 6, promote the production of tissue factor (TF) and von Willebrand factor (vWF) and aggravate endothelial dysfunction leading to increased coagulation and depressed fibrinolytic activity. The interaction of vWF and glycoprotein Ib (vWF-GPIb) receptor activates 'thrombo-inflammatory' pathways promoting thromboembolism. Moreover, platelet activation driven by plateletleukocyte/ monocyte interaction attribute to AF-related thrombosis. Biochemical pathways such as CD40-CD40 ligand and P-selectin-P-selectin glycoprotein ligand 1 are considered important mediators of platelet-leukocyte interactions in the setting of AF. Further studies are required to address the clinical implications of inflammatory biomarkers in the prediction of AF-related thromboembolism. Indeed, inflammatory pathways could be also considered as therapeutic targets in an effort to reduce the clinical consequences of thromboembolism and improve outcomes in AF.
Keywords: Atrial fibrillation, stroke, inflammation, Virchow's triad, endothelial dysfunction, platelet activation.
Current Vascular Pharmacology
Title:Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Volume: 13 Issue: 2
Author(s): Yutao Guo, Gregory Y.H. Lip and Stavros Apostolakis
Affiliation:
Keywords: Atrial fibrillation, stroke, inflammation, Virchow's triad, endothelial dysfunction, platelet activation.
Abstract: Inflammation, endothelial dysfunction, and platelet activation contribute to the prothrombotic pro-inflammatory state associated with AF. Inflammatory biomarkers, such as C-reactive protein and interleukin 6, promote the production of tissue factor (TF) and von Willebrand factor (vWF) and aggravate endothelial dysfunction leading to increased coagulation and depressed fibrinolytic activity. The interaction of vWF and glycoprotein Ib (vWF-GPIb) receptor activates 'thrombo-inflammatory' pathways promoting thromboembolism. Moreover, platelet activation driven by plateletleukocyte/ monocyte interaction attribute to AF-related thrombosis. Biochemical pathways such as CD40-CD40 ligand and P-selectin-P-selectin glycoprotein ligand 1 are considered important mediators of platelet-leukocyte interactions in the setting of AF. Further studies are required to address the clinical implications of inflammatory biomarkers in the prediction of AF-related thromboembolism. Indeed, inflammatory pathways could be also considered as therapeutic targets in an effort to reduce the clinical consequences of thromboembolism and improve outcomes in AF.
Export Options
About this article
Cite this article as:
Guo Yutao, Lip Y.H. Gregory and Apostolakis Stavros, Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/15701611113116660165
DOI https://dx.doi.org/10.2174/15701611113116660165 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
eNOS Uncoupling in Cardiovascular Diseases - the Role of Oxidative Stress and Inflammation
Current Pharmaceutical Design Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions
Current Drug Delivery Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Drug Eluting Stents: Friend or Foe? A Review of Cellular Mechanisms Behind the Effects of Paclitaxel and Sirolimus Eluting Stents
Current Drug Metabolism Gender-specific, Lifestyle-related Factors and 10-year Cardiovascular Disease Risk; the ATTICA and GREECS Cohort Studies
Current Vascular Pharmacology Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Prostacyclin Receptor Regulation --- from Transcription to Trafficking
Current Molecular Medicine An Insight to Colon Targeted Drug Delivery System
Drug Delivery Letters Adult Stem Cells and Biocompatible Scaffolds as Smart Drug Delivery Tools for Cardiac Tissue Repair
Current Medicinal Chemistry Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design The Prospect for Type 2 Diabetes Mellitus Combined with Exercise and Synbiotics: A Perspective
Current Diabetes Reviews Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology The Pamela Study: Old and New Findings
Current Hypertension Reviews The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin
Current Cardiology Reviews Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Coronary Artery Aneurysms as a Cause of Acute Coronary Syndrome Presentation - A Focused Review
Current Cardiology Reviews Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design